Acquired von Willebrand disease in monoclonal gammapathies: Effectiveness of high-dose intravenous gamma globulin

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue 3, 1999, Pages 152-157

  Michiels, Jan Jacques ^a,b   Van Vliet, Huub H D M ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Goodheart Institute   (Netherlands)

^c NONE

Author keywords

Acquired von Willebrand syndrome; Intravenous gamma globulin; Monoclonal gammapathy

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING TIME; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; GAMMOPATHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

EID: 0033013698     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969900500302     Document Type: Article

References (14)

1. Ivy AC, Nelson D, Bucher GNH. The standardization of certain factors in the cutaneous "venostasis" bleeding time technique. J Lab Clin Med 1941;26:1812.
2. van Genderen PJJ, Vink T, Michiels JJ, et al. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of the von Willebrand factor to collagen. Blood 1994; 84:3378.
3. Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982;26:1812.
4. Macfarlane DE, Stibbe J, Kirby EP, et al. A method for assaying von Willebrand factor (Risticetine cofactor) Thromb Diath Haemorrh 1975;34:306.
5. Brown JE, Bosak JO. Al ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986;43:303.
6. Brosstad F, Kjönniksen I, Ronning B. Stormorken H. Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 1986;55:276.
7. Kaspar CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:869.
8. van Genderen PJJ, Michiels JJ, Bakker JJ, van't Veer MB. Effectiveness of high-dose intravenous gammaglobulin therapy in acquired von Willebrand's disease. Vox Sang 1994;67:14.
9. van Genderen PJJ, Papatsonis DNM, Michiels JJ, et al. High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease. Postgrad Med J 1994;70:916.
10. van Genderen PJJ, Terpstra W, Michiels JJ. et al. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemos 1995; 73:890.
11. Fricke WA, Brinkhous KM, Garris JB, Roberts GnR. Comparison of inhibitory and binding characteristics of an antibody causing von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood 1985;66:562-569.
12. Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood 1976;48:393.
13. Kobayashi N, Gonmori H. Acquired von Willebrand's syndrome with special reference to its clinical characteristics and pathogenesis. Acta Haematol Japonica 1979;42:883.
14. van Genderen PJJ, Michiels JJ. Acquired von Willebrand disease. Baillières Clin Haematol 1998;11:319.